177 related articles for article (PubMed ID: 32496210)
1. Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19.
Xie X; Jiang Y; Zeng Y; Liu H
Antivir Ther; 2020; 25(4):233-239. PubMed ID: 32496210
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome.
Kim UJ; Won EJ; Kee SJ; Jung SI; Jang HC
Antivir Ther; 2016; 21(5):455-9. PubMed ID: 26492219
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol.
Zeng YM; Xu XL; He XQ; Tang SQ; Li Y; Huang YQ; Harypursat V; Chen YK
Chin Med J (Engl); 2020 May; 133(9):1132-1134. PubMed ID: 32149772
[No Abstract] [Full Text] [Related]
4. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.
Zhu Z; Lu Z; Xu T; Chen C; Yang G; Zha T; Lu J; Xue Y
J Infect; 2020 Jul; 81(1):e21-e23. PubMed ID: 32283143
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats.
Hu Y; Zuo M; Wang X; Wang R; Li L; Lu X; Jiang S
J Zhejiang Univ Sci B; 2021 Jul; 22(7):599-602. PubMed ID: 34269012
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.
Smolders EJ; Te Brake LH; Burger DM
Antivir Ther; 2020; 25(7):345-347. PubMed ID: 32589165
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019.
Yu M; Wang DC; Li S; Lei YH; Wei J; Huang LY
J Med Virol; 2022 Apr; 94(4):1513-1522. PubMed ID: 34837230
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
10. Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study.
Yin P; Meng J; Chen J; Gao J; Wang D; Liu S; Guo Q; Zhu M; Zhang G; Liu Y; Li Y; Zhang G
Virol J; 2021 Jul; 18(1):142. PubMed ID: 34238341
[TBL] [Abstract][Full Text] [Related]
11. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.
Wang N; Zhan Y; Zhu L; Hou Z; Liu F; Song P; Qiu F; Wang X; Zou X; Wan D; Qian X; Wang S; Guo Y; Yu H; Cui M; Tong G; Xu Y; Zheng Z; Lu Y; Hong P
Cell Host Microbe; 2020 Sep; 28(3):455-464.e2. PubMed ID: 32707096
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial.
Liu P; Huang Z; Yin M; Liu C; Chen X; Pan P; Kuang Y
Trials; 2020 Dec; 21(1):999. PubMed ID: 33276811
[TBL] [Abstract][Full Text] [Related]
13. Quadruple therapy for asymptomatic COVID-19 infection patients.
Wang L; Xu X; Ruan J; Lin S; Jiang J; Ye H
Expert Rev Anti Infect Ther; 2020 Jul; 18(7):617-624. PubMed ID: 32362193
[TBL] [Abstract][Full Text] [Related]
14. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
Deng L; Li C; Zeng Q; Liu X; Li X; Zhang H; Hong Z; Xia J
J Infect; 2020 Jul; 81(1):e1-e5. PubMed ID: 32171872
[TBL] [Abstract][Full Text] [Related]
15. Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice.
Levy C; Lassailly G; Parmentier E; Duburcq T; Mathurin P; Poissy J
Am J Gastroenterol; 2020 Oct; 115(10):1716-1718. PubMed ID: 32858566
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study.
Liu X; Chen H; Shang Y; Zhu H; Chen G; Chen Y; Liu S; Zhou Y; Huang M; Hong Z; Xia J
Trials; 2020 Jul; 21(1):622. PubMed ID: 32641091
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.
Li Y; Xie Z; Lin W; Cai W; Wen C; Guan Y; Mo X; Wang J; Wang Y; Peng P; Chen X; Hong W; Xiao G; Liu J; Zhang L; Hu F; Li F; Zhang F; Deng X; Li L
Med; 2020 Dec; 1(1):105-113.e4. PubMed ID: 32838353
[TBL] [Abstract][Full Text] [Related]
18. Infection of severe acute respiratory syndrome coronavirus 2 in a patient with AIDS.
Su J; Shen X; Ni Q; Zhao H; Cai J; Zhu B; Wu W; Lang G; Xu K; Sheng J
AIDS; 2020 Aug; 34(10):1575-1576. PubMed ID: 32675569
[No Abstract] [Full Text] [Related]
19. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
Vernaz N; Agoritsas T; Calmy A; Gayet-Ageron A; Gold G; Perrier A; Picard F; Prendki V; Reny JL; Samer C; Stirnemann J; Vetter P; Zanella MC; Zekry D; Baggio S
Swiss Med Wkly; 2020 Dec; 150():w20446. PubMed ID: 33382449
[TBL] [Abstract][Full Text] [Related]
20. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
